|
CN1020944C
(zh)
|
1990-01-30 |
1993-05-26 |
阿图尔-费希尔股份公司费希尔厂 |
紧固件
|
|
CA2429833A1
(en)
*
|
2000-11-30 |
2002-06-06 |
Kissei Pharmaceutical Co., Ltd. |
Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof
|
|
TWI255817B
(en)
*
|
2001-02-14 |
2006-06-01 |
Kissei Pharmaceutical |
Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof
|
|
JP4651934B2
(ja)
*
|
2002-12-04 |
2011-03-16 |
キッセイ薬品工業株式会社 |
ベンジルフェノール誘導体、それを含有する医薬組成物およびその医薬用途
|
|
US20060035844A1
(en)
*
|
2002-12-04 |
2006-02-16 |
Fumiaki Ito |
Preventive or remedy for diseases caused by hyperglycemia
|
|
DE10258008B4
(de)
*
|
2002-12-12 |
2006-02-02 |
Sanofi-Aventis Deutschland Gmbh |
Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
|
|
DE10258007B4
(de)
|
2002-12-12 |
2006-02-09 |
Sanofi-Aventis Deutschland Gmbh |
Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
|
|
AU2003902263A0
(en)
*
|
2003-05-12 |
2003-05-29 |
Fujisawa Pharmaceutical Co., Ltd. |
Monosaccharide compounds
|
|
UA86042C2
(en)
*
|
2003-08-01 |
2009-03-25 |
Янссен Фармацевтика Н.В. |
Substituted indazole-o-glucosides
|
|
US7371732B2
(en)
*
|
2003-12-22 |
2008-05-13 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyloxy-substituted aromatic compounds, medicaments containing such compounds, their use and process for their manufacture
|
|
PL1730131T3
(pl)
|
2004-03-16 |
2012-10-31 |
Boehringer Ingelheim Int |
Glukopiranozylo-podstawione pochodne benzenu, środki lecznicze zawierające te związki, ich zastosowanie i sposób ich wytwarzania
|
|
CA2560005A1
(en)
*
|
2004-03-31 |
2005-10-13 |
Kissei Pharmaceutical Co., Ltd. |
Phenol derivative, medicinal composition containing the same, and medicinal use thereof
|
|
TW200606129A
(en)
|
2004-07-26 |
2006-02-16 |
Chugai Pharmaceutical Co Ltd |
Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
|
|
EP1828216B1
(en)
|
2004-12-16 |
2008-09-10 |
Boehringer Ingelheim International GmbH |
Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
|
|
TW200637869A
(en)
|
2005-01-28 |
2006-11-01 |
Chugai Pharmaceutical Co Ltd |
The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
|
|
JP5073948B2
(ja)
*
|
2005-01-31 |
2012-11-14 |
田辺三菱製薬株式会社 |
医薬組成物
|
|
JP5264183B2
(ja)
|
2005-02-23 |
2013-08-14 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
グルコピラノシル置換((ヘテロ)アリールエチニル−ベンジル)−ベンゼン誘導体及びナトリウム依存性グルコース共輸送体2(sglt2)インヒビターとしてのそれらの使用
|
|
DE602006011453D1
(de)
|
2005-04-15 |
2010-02-11 |
Boehringer Ingelheim Pharma |
Glucopyranosyl-substituierte (heteroaryloxy-benzyl)-benzen-derivate als sglt-inhibitoren
|
|
US7723309B2
(en)
|
2005-05-03 |
2010-05-25 |
Boehringer Ingelheim International Gmbh |
Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
|
|
UA91546C2
(uk)
|
2005-05-03 |
2010-08-10 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
|
|
US7772191B2
(en)
|
2005-05-10 |
2010-08-10 |
Boehringer Ingelheim International Gmbh |
Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
|
|
EP1910390B1
(en)
|
2005-07-27 |
2010-05-19 |
Boehringer Ingelheim International GmbH |
Glucopyranosyl-substituted ((hetero)cycloalyklethynyl-benzyl)-benzene derivatives and use thereof as sodium-dependent glucose cotransporter (sglt) inhibitors
|
|
ATE484499T1
(de)
|
2005-08-30 |
2010-10-15 |
Boehringer Ingelheim Int |
Glucopyranosyl-substituierte benzyl-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür
|
|
BRPI0615882A2
(pt)
|
2005-09-08 |
2011-05-31 |
Boehringer Ingelheim Int |
formas cristalinas de 1-cloro-4-(beta-d-glicopiranos-1-il)-2-(4-etinil-benzil)- benzeno, métodos para sua preparação e o uso para preparar medicamentos do mesmo
|
|
AR056195A1
(es)
|
2005-09-15 |
2007-09-26 |
Boehringer Ingelheim Int |
Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
|
|
ATE517099T1
(de)
|
2006-02-15 |
2011-08-15 |
Boehringer Ingelheim Int |
Glucopyranosyl-substituierte benzonitril-derivate,pharmazeutische zusammensetzungen mit derartigen verbindungen, ihre verwendung und herstellungsverfahren dafür
|
|
PE20080697A1
(es)
|
2006-05-03 |
2008-08-05 |
Boehringer Ingelheim Int |
Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
|
|
PE20080251A1
(es)
|
2006-05-04 |
2008-04-25 |
Boehringer Ingelheim Int |
Usos de inhibidores de dpp iv
|
|
DE102006028862A1
(de)
|
2006-06-23 |
2007-12-27 |
Merck Patent Gmbh |
3-Amino-imidazo[1,2-a]pyridinderivate
|
|
TW200817424A
(en)
|
2006-08-04 |
2008-04-16 |
Daiichi Sankyo Co Ltd |
Benzylphenyl glucopyranoside derivatives
|
|
TWI499414B
(zh)
|
2006-09-29 |
2015-09-11 |
Lexicon Pharmaceuticals Inc |
鈉與葡萄糖第2型共同運輸體(co-transporter 2)的抑制物與其應用方法
|
|
EP2094683B1
(en)
|
2006-12-06 |
2011-10-12 |
GlaxoSmithKline LLC |
Bicyclic compounds and use as antidiabetics
|
|
DE102007008420A1
(de)
|
2007-02-21 |
2008-08-28 |
Merck Patent Gmbh |
Benzimidazolderivate
|
|
US7846945B2
(en)
*
|
2007-03-08 |
2010-12-07 |
Lexicon Pharmaceuticals, Inc. |
Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use
|
|
WO2009014970A1
(en)
*
|
2007-07-26 |
2009-01-29 |
Lexicon Pharmaceuticals, Inc. |
Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors
|
|
PE20090938A1
(es)
|
2007-08-16 |
2009-08-08 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
|
|
DE102007048716A1
(de)
|
2007-10-11 |
2009-04-23 |
Merck Patent Gmbh |
Imidazo[1,2-a]pyrimidinderivate
|
|
WO2009096503A1
(ja)
*
|
2008-01-31 |
2009-08-06 |
Daiichi Sankyo Company, Limited |
ベンジルフェニルグルコピラノシド誘導体
|
|
DE102008017590A1
(de)
|
2008-04-07 |
2009-10-08 |
Merck Patent Gmbh |
Glucopyranosidderivate
|
|
US9061060B2
(en)
|
2008-07-15 |
2015-06-23 |
Theracos Inc. |
Deuterated benzylbenzene derivatives and methods of use
|
|
CN102149717B
(zh)
*
|
2008-08-28 |
2014-05-14 |
辉瑞大药厂 |
二氧杂-双环[3.2.1]辛烷-2,3,4-三醇衍生物
|
|
PE20120017A1
(es)
|
2009-02-13 |
2012-02-12 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende un inhibidor de sglt2, un inhibidor de dpp-iv, opcionalmente, un agente antidiabetico adicional, y sus usos
|
|
EA020798B1
(ru)
|
2009-09-30 |
2015-01-30 |
Бёрингер Ингельхайм Интернациональ Гмбх |
СПОСОБ ПОЛУЧЕНИЯ КРИСТАЛЛИЧЕСКОЙ ФОРМЫ 1-ХЛОР-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГИДРОФУРАН-3-ИЛОКСИ)БЕНЗИЛ]БЕНЗОЛА
|
|
CA2775962C
(en)
|
2009-09-30 |
2017-09-05 |
Boehringer Ingelheim International Gmbh |
Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives
|
|
US10610489B2
(en)
|
2009-10-02 |
2020-04-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
|
|
CN102753184A
(zh)
|
2009-10-02 |
2012-10-24 |
赛诺菲 |
具有sglt-1/sglt-2抑制剂活性的化合物在制备用于治疗骨病的药物中的用途
|
|
PL2496583T3
(pl)
|
2009-11-02 |
2015-04-30 |
Pfizer |
Pochodne dioksabicyklo[3.2.1]oktano-2,3,4-triolowe
|
|
WO2011070592A2
(en)
|
2009-12-09 |
2011-06-16 |
Panacea Biotec Ltd. |
Novel sugar derivatives
|
|
WO2011107494A1
(de)
|
2010-03-03 |
2011-09-09 |
Sanofi |
Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
JP2013523681A
(ja)
|
2010-03-30 |
2013-06-17 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Sglt2インヒビター及びppar−ガンマアゴニストを含む医薬組成物並びにその使用
|
|
US20120283169A1
(en)
|
2010-11-08 |
2012-11-08 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
US20130035281A1
(en)
|
2011-02-09 |
2013-02-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
UY33937A
(es)
|
2011-03-07 |
2012-09-28 |
Boehringer Ingelheim Int |
Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
|
|
PH12013502487A1
(en)
|
2011-06-03 |
2014-01-20 |
Boehringer Ingelheim Int |
Sglt-2 inhibitors for treating metabolic disorders in patients treated with neuroleptic agents
|
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
|
US9192617B2
(en)
|
2012-03-20 |
2015-11-24 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
EP2774619B1
(de)
|
2013-03-04 |
2016-05-18 |
BioActive Food GmbH |
Zusammensetzung zur Behandlung von hyperglykämischen Erkrankungen
|
|
ES2740299T3
(es)
|
2013-03-14 |
2020-02-05 |
Msd Int Gmbh |
Métodos para preparar inhibidores de SGLT2
|
|
EP2981269B9
(en)
|
2013-04-04 |
2023-12-06 |
Boehringer Ingelheim Vetmedica GmbH |
Treatment of metabolic disorders in equine animals
|
|
HK1213818A1
(zh)
|
2013-04-05 |
2016-07-15 |
勃林格殷格翰国际有限公司 |
依帕列净的治疗用途
|
|
US11813275B2
(en)
|
2013-04-05 |
2023-11-14 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
CA2812519A1
(en)
|
2013-04-05 |
2014-10-05 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
ES2702174T3
(es)
|
2013-04-05 |
2019-02-27 |
Boehringer Ingelheim Int |
Usos terapéuticos de empagliflozina
|
|
JP2016520564A
(ja)
|
2013-04-18 |
2016-07-14 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
医薬組成物、治療方法及びその使用
|
|
ES2859905T3
(es)
|
2013-12-17 |
2021-10-04 |
Boehringer Ingelheim Vetmedica Gmbh |
Inhibidores de SGLT2 para el tratamiento de trastornos metabólicos en animales felinos
|
|
KR20220097538A
(ko)
|
2014-01-23 |
2022-07-07 |
베링거잉겔하임베트메디카게엠베하 |
개과 동물에서 대사 장애의 치료
|
|
PL3125882T3
(pl)
|
2014-04-01 |
2020-10-19 |
Boehringer Ingelheim Vetmedica Gmbh |
Leczenie zaburzeń metabolicznych u zwierząt koniowatych
|
|
EP2944311A1
(de)
|
2014-05-16 |
2015-11-18 |
BioActive Food GmbH |
Kombination von biologisch aktiven Substanzen zur Behandlung von hyperglykämischen Erkrankungen
|
|
MX388515B
(es)
|
2014-06-24 |
2025-03-20 |
Univ Kansas |
Bifenil amidas con grupos éter modificados como inhibidores de hsp90 e inductores de hsp70.
|
|
DK3197429T3
(da)
|
2014-09-25 |
2024-08-26 |
Boehringer Ingelheim Vetmedica Gmbh |
Kombinationsbehandling med sglt2-hæmmere og dopaminagonister til forebyggelse af metaboliske lidelser af dyr i hestefamilien
|
|
US20210212968A1
(en)
|
2016-10-19 |
2021-07-15 |
Boehringer Ingelheim International Gmbh |
Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
|
|
MX2019005435A
(es)
|
2016-11-10 |
2019-07-10 |
Boehringer Ingelheim Int |
Composicion farmaceutica, metodos para tratamiento y sus usos.
|
|
AU2019254371A1
(en)
|
2018-04-17 |
2020-10-08 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
|
EP3794009A1
(en)
|
2018-05-14 |
2021-03-24 |
Reata Pharmaceuticals, Inc. |
Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway
|
|
CN112955214B
(zh)
|
2018-10-29 |
2024-05-07 |
勃林格殷格翰国际有限公司 |
吡啶基磺酰胺衍生物、药物组合物及其用途
|
|
FI3873600T3
(fi)
|
2018-10-29 |
2023-12-07 |
Boehringer Ingelheim Int |
Pyridinyylisulfonamidijohdannaisia, farmaseuttisia koostumuksia ja niiden käytöt
|
|
UY38969A
(es)
|
2019-11-28 |
2021-05-31 |
Boehringer Ingelheim Vetmedica Gmbh |
Uso de inhibidores de sglt-2 en el secado de mamíferos no humanos
|
|
CN118615450A
(zh)
|
2020-02-17 |
2024-09-10 |
勃林格殷格翰动物保健有限公司 |
Sglt-2抑制剂用于预防和/或治疗猫科动物的心脏疾病的用途
|
|
EP4376819A1
(en)
|
2021-07-28 |
2024-06-05 |
Boehringer Ingelheim Vetmedica GmbH |
Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
|
|
WO2023006747A1
(en)
|
2021-07-28 |
2023-02-02 |
Boehringer Ingelheim Vetmedica Gmbh |
Use of sglt-2 inhibitors for the prevention and/or treatment of renal diseases in non-human mammals
|
|
KR20240041966A
(ko)
|
2021-07-28 |
2024-04-01 |
베링거잉겔하임베트메디카게엠베하 |
고양이를 제외한 비인간 포유류, 특히 개에서 심장 질환의 예방 및/또는 치료를 위한 sglt-2 억제제의 용도
|
|
AU2022425078A1
(en)
|
2021-12-30 |
2024-08-08 |
Newamsterdam Pharma B.V. |
Obicetrapib and sglt2 inhibitor combination
|
|
CN114933619B
(zh)
*
|
2022-05-18 |
2024-03-01 |
上海科利生物医药有限公司 |
一类硫代糖苷列净类似物及其制备方法和应用
|
|
AU2023277704A1
(en)
|
2022-05-25 |
2024-12-05 |
Boehringer Ingelheim Vetmedica Gmbh |
Aqueous pharmaceutical compositions comprising sglt-2 inhibitors
|
|
US20240307628A1
(en)
|
2023-03-06 |
2024-09-19 |
Boehringer Ingelheim Vetmedica Gmbh |
Systems and methods for delivery of liquid pharmaceutical compositions in particular comprising one or more sglt-2 inhibitor(s)
|
|
AR132497A1
(es)
|
2023-04-24 |
2025-07-02 |
Newamsterdam Pharma B V |
Combinación de obicetrapib amorfo e inhibidor de sglt2
|
|
WO2024240633A1
(en)
|
2023-05-24 |
2024-11-28 |
Boehringer Ingelheim Vetmedica Gmbh |
Combination treatment and/or prevention of renal diseases and/or hypertension in non-human mammals comprising one or more sglt-2 inhibitors and telmisartan
|
|
AU2024276892A1
(en)
|
2023-05-24 |
2025-10-16 |
Boehringer Ingelheim Vetmedica Gmbh |
Combination treatment and/or prevention of cardiac diseases in non-human mammals comprising one or more sglt-2 inhibitors and pimobendan and/or telmisartan
|